How to Register a Pesticide in Japan: FAMIC, Dossiers, Timelines

An initial pesticide registration in Japan carries a published standard processing period of 18 months, and Japan grants roughly 120 of them a year.

Those two numbers frame the whole exercise. Eighteen months is long enough that registration has to be treated as a capital project rather than a filing, and 120 a year tells you the reviewing body is not processing volume: each application receives real scrutiny.

This guide covers who registers and who reviews, what the dossier must contain, the two routes open to a foreign manufacturer, what the file can and cannot be submitted in, the online filing position, the statutory fees, and the obligations that continue after a registration is granted. The governing statute is the Agricultural Chemicals Regulation Act (農薬取締法), administered by MAFF with review work carried out through FAMIC.

If you would rather have someone run this process for you, we do that: see our Japan pesticide registration support for foreign agrochemical companies. The rest of this article explains the system you would be paying to navigate.

Who registers, and who reviews

Five bodies touch a Japanese pesticide registration, and confusing their roles is the most common early mistake.

• MAFF (農林水産省) grants the registration. Every pesticide manufactured, processed, or imported for sale in Japan must be registered with the Minister of Agriculture, Forestry and Fisheries.
• FAMIC (農林水産消費安全技術センター), through its Agricultural Chemicals Inspection Station (ACIS), examines the application, the sample, and the study reports, and reports to the Minister. FAMIC also runs the mandatory pre-submission contact and the GLP compliance programme for the toxicology, mutagenicity, and related studies. As of 30 September 2025, 3,908 products across 577 active ingredients hold current registrations.
• The Food Safety Commission (食品安全委員会) sets the acceptable daily intake and acute reference dose from the metabolism and toxicology data. It works in Japanese, which is why those summaries must be Japanese.
• The Ministry of the Environment (環境省) assesses effects on organisms in the human environment and on water quality.
• The Consumer Affairs Agency (消費者庁) sets the maximum residue limits under the Food Sanitation Act, working from the Food Safety Commission’s ADI, which is what makes a registration usable on food crops.

A registration application is therefore reviewed by a chain, not a single desk. That is the structural reason the published processing period and the observed elapsed time diverge, which this article returns to below.

What the dossier must contain

FAMIC’s own description is the clearest statement of the requirement: an applicant submits the application form, a sample where required, and a dossier including data on efficacy, phytotoxicity, toxicity, residues, and other prescribed matters. The detailed data requirements are set by MAFF Notice 30-Shouan-6278 (data requirements for registration), with companion notices on crop and pest names and on the documents to be attached. Separate guidelines cover microbial and natural-enemy pesticides. FAMIC publishes reference translations of all of these on its English data requirements page, with the caution that only the Japanese texts have legal effect.

Which studies actually apply depends on the formulation, the use pattern, and the crops, so the practical first step for any foreign manufacturer is a gap assessment: laying your existing dossier against the 6278 tables and identifying what is already covered, what needs a Japanese-specific study, and what can be argued away with a written justification. Where a study is absent, a method other than the prescribed one was used, or a guideline changed within six months of filing, the guidance expects a written rationale. Translation scope, the study programme, and the timeline all fall out of that assessment.

The generic and off-patent route

For mature active ingredients there is a defined shortcut. The 2018 amendment to the Act introduced Article 3(3), under which an applicant can be exempted from part of the required test data where the active ingredient is equivalent in composition and toxicity to an active already registered in Japan. From 1 December 2018 the application must also declare the non-active components of the technical material, the manufacturer, and the manufacturing process, which is what the equivalence assessment is made against (MAFF, 2018 amendment overview).

Two things follow. The exemption is not automatic: equivalence has to be demonstrated, typically with batch analysis and impurity profiling of the technical material, and claimed in the application. And it changes the economics of a generic entry materially, because a targeted package replaces a full one. Generic manufacturers who assume Japan requires a complete data set, or who assume it accepts a reference to the originator’s data as some jurisdictions do, are both wrong in ways that cost time.

The two registration routes, and why one is almost unused

There are two ways a pesticide reaches the Japanese market, and the filing volumes tell a clearer story than the statute does.

Route	Legal basis	Standard period	Filings/year
Standard registration, held by a Japanese registrant	Art. 3(2)	18 months	~120
Foreign-manufactured pesticide registration, held by the foreign manufacturer	Art. 34	18 months	~1

The foreign-manufacturer route exists and it is real. Article 34 lets a company that manufactures or processes a pesticide abroad for export to Japan register it in its own name. The condition is in Article 34(2): at the time of application the applicant must appoint a domestic administrator (国内管理人), a person domiciled in Japan, which can include the representative of a Japanese office of a foreign company, whose job is to ensure measures are taken in Japan to prevent substandard product reaching the market. Articles 34 to 37 then attach the duties: the registered foreign manufacturer keeps a ledger of manufacturing and shipment quantities to Japan and notifies them to the administrator, who keeps a corresponding ledger; a change of administrator must be notified within one month; MAFF and the Ministry of the Environment can order reports from the administrator and inspect the premises; importers of the product must notify MAFF; and a vacancy in the post that is not refilled is grounds for cancelling the registration.

It is used approximately once a year. Registration is overwhelmingly done through a Japanese applicant of record holding the registration, rather than by the foreign manufacturer in its own name. The reasons are practical rather than legal: the holder carries the reporting duties, answers review questions in Japanese, handles the label, and manages the re-evaluation cycle, and most foreign companies have a Japanese distributor or partner willing to do that.

The trade-off is ownership. A registration held by a Japanese registrant belongs to the registrant. A registration held under Article 34 belongs to you, to license, transfer, or supply against, at the cost of maintaining a domestic administrator and the duties that come with it. Choosing between the two is one of the first commercial decisions, not a late administrative one, because the registration sits with whoever holds it. We advise on that choice and manage the process on either route, and for select clients we act as domestic administrator.

The dossier: mostly English, since 2014

This is the part most often misunderstood, in both directions.

MAFF has accepted OECD dossier formats since 15 May 2014, under the dossier guidance notice 26消安第537号. The rule on medium and language is specific:

• Full study reports are submitted as electronic records only, with no paper copy, and may be in English.
• The summary and discussion document may also be in English, except for four carved-out categories.

Those four exceptions must be in Japanese:

1. Metabolism in animals
2. The entire human-health toxicology package, covering acute, short-term and long-term toxicity, genotoxicity, carcinogenicity, reproductive toxicity and neurotoxicity
3. Metabolism in plants
4. Metabolism in livestock

The pattern is coherent once you see the reason. The Food Safety Commission sets the acceptable daily intake and acute reference dose from the metabolism and toxicology material, and it works in Japanese. Everything feeding the health risk assessment stays Japanese; everything else, including every underlying full report, may be English.

For a company planning a submission, this converts a vague and expensive question, how much of this needs translating, into a deterministic one. The carve-outs are four defined clauses. Translation scope can be decided from the dossier inventory rather than by habit, and translation is a real budget line.

Two cautions. This has been the position since 2014, so it is not a new opening and should not be treated as one. And “English is accepted” is not the same as “English is sufficient”: the four carve-outs sit precisely where the scientific argument is hardest and where a poor translation does the most damage.

What the government charges

The statutory fees are published by MAFF and are the same whoever files (農薬の登録申請等に係る手数料について):

Application	Fee
New registration (登録申請)	¥719,300
Change registration, new crop or pest (変更登録申請)	¥251,700
Re-registration (再登録申請)	¥73,200
Registration certificate issue or reissue	¥2,400

These are the small part of the cost. The large part is the study programme, and that depends entirely on the gap between your existing dossier and the 6278 requirements, which is why a credible cost estimate starts with an assessment rather than a price list.

Online filing: real, but partial

Procedures under the Act are unusually digitised. 78 percent are available online, against a government-wide average of roughly 49 percent. eMAFF supports electronic pesticide applications.

Three qualifications matter before anyone plans around that:

• Prior contact with the registration section is mandatory before filing. This is not a portal you simply submit into.
• Physical samples are still required where the active ingredient is not already registered.
• Four of the five dossier components still require paper alongside the electronic submission.

So the accurate statement is that filing is electronic-first with paper and physical obligations remaining, not that the process is online.

After registration: extension and re-evaluation

A registration is not a terminal state, and the two follow-on procedures both carry long clocks.

Procedure	Legal basis	Standard period	Filings/year
Change registration, extending pest or crop scope	Art. 7(1)	9 months	~820
Re-evaluation application	Art. 8(7)	12 months published, 3.8 years observed	~500
Registration certificate amendment notification	Art. 6(2)	same day	~3,300
Production, import volume and safety reporting	Art. 18	1 day	~160

Extending an existing registration to a new crop or pest takes nine months. For a company building a Japanese portfolio incrementally, that is the number that governs the roadmap: each additional use pattern is most of a year, and the 820 annual filings show this is where most of the activity actually is, not in new registrations.

Re-evaluation runs to 12 months, with about 500 processed a year. This is a recurring obligation attached to registrations already granted, and it consumes regulatory capacity that companies planning only for initial registration tend not to budget.

By contrast, administrative changes to the registration certificate are same-day and free, and run to roughly 3,300 a year. The distinction between an administrative change and a change registration is therefore worth understanding precisely, because one is instant and the other is three quarters.

Timing your filing against the re-evaluation cycle

The four procedures above are not independent, and treating them as separate queues is the mistake worth avoiding.

Re-evaluation is not ad hoc. The 2018 amendment to the Act established a fifteen-year cycle covering every registered pesticide, and it began in October 2021, sequenced by priority level assigned per active ingredient, with the highest domestic usage and greatest public-health and environmental impact taken first. MAFF publishes both the list of actives due for re-evaluation and the data submission deadline for each.

That single fact changes how the timings should be read: the window applying to your active is knowable years ahead, not something that arrives unannounced.

Two consequences follow.

The data packages overlap. A re-evaluation requires a fresh data package assessed against current standards. A change registration requires data supporting the new use pattern. Where both fall in the same period, the studies substantially overlap, and companies that plan them separately generate work twice. Aligning an intended extension with a known re-evaluation deadline is the difference between one data programme and two.

The reviews compete for the same capacity. Every route runs through the same reviewing centre, and the corpus shows the shape of that pipeline:

Review instruction	Legal basis	Per year
New registration	Art. 3(5)	~120
Change registration	Art. 7(3)	~820
Re-evaluation	Art. 8(5)	~500
		~1,440 total

Re-evaluation now accounts for roughly a third of all review instructions, on a system that did not carry that load before 2021. The published standard processing periods are the reviewing body’s own targets, and they are targets set against a workload that has structurally grown.

The four review tracks, decided by one date

Filing during a re-evaluation period is not prohibited, and the treatment is not discretionary. It is set out in MAFF Notice 4177 (元消安第4177号, Pesticide Control Office, 25 December 2019, amended 1 April 2025), which governs the handling of applications for pesticides subject to re-evaluation and for products sharing the same active ingredient.

Section 3 of that notice establishes four review tracks, and which one applies is decided by a single variable: where your filing date falls relative to that active ingredient’s published data-submission deadline (提出期限日).

Track	Filing window	Result	What it means
1	2 years or more before the deadline	Normal review	Reviewed as usual. If not concluded by the deadline, it continues alongside the re-evaluation.
2	Between 2 years and 1 year before	Parallel review	Reviewed together with the re-evaluation, or normally where the review needs under a year.
3	Within 1 year of the deadline	Parallel review	Reviewed at the same time as the re-evaluation.
4	After the deadline	Deferred review	Review begins only once the re-evaluation concludes, unless the re-evaluation data already covers the application.

Track 4 is the one to plan around. File after the deadline and your review does not start until the re-evaluation finishes. That sounds like a twelve-month wait, because twelve months is the published standard processing period for a re-evaluation. It is not what the published progress data shows, and the gap is the single most important number in this article.

The practical rule that falls out of this is unusually clean for a regulatory question. The deadline for your active is published in advance. Your filing date is within your control. Those two facts together determine your track, so the decision is a scheduling one made deliberately, rather than an outcome discovered afterwards.

Filing two or more years ahead of the deadline keeps you on a normal review. Between one and two years, expect the review to be run alongside the re-evaluation. Inside a year, expect it to be parallel as a matter of course. Past the deadline, expect to wait.

The published period is twelve months. Every completed re-evaluation has taken close to four.

MAFF publishes both the data-submission deadline for each active ingredient and, separately, the pesticides whose re-evaluation has concluded, with the date the registration certificate was issued. Those two sources can be joined. As published on 5 August 2026, seven re-evaluations have completed, and this is every one of them:

Active ingredient	Data deadline	Concluded	Elapsed
Esprocarb	30 Jun 2022	24 Dec 2025	3.49 yrs
Thifluzamide	28 Dec 2021	28 Aug 2025	3.67 yrs
Ferimzone	30 Sep 2022	22 Jul 2026	3.81 yrs
Pentoxazone	30 Sep 2022	22 Jul 2026	3.81 yrs
Butachlor	28 Dec 2021	29 Oct 2025	3.84 yrs
Phenmedipham	30 Jun 2022	10 Jun 2026	3.95 yrs
Isotianil	31 Mar 2022	8 Apr 2026	4.02 yrs

Mean 3.8 years. Range 3.5 to 4.0. Not one completed within the published twelve-month period, and none came close. The consistency is as striking as the length: every case lands in a seven-month band around four years, which suggests a structural duration rather than a backlog that might clear.

The actives still running are further out. The 2021 priority cohort, selected for highest domestic usage, had a deadline of 28 December 2021. Several of them, including thiamethoxam, acetamiprid and dinotefuran, had logged only three or four of roughly sixteen assessment milestones as of August 2026, four and a half years on and still short of conclusion.

Why the gap? Re-evaluation is not one review. It runs across MAFF, the Food Safety Commission, the Consumer Affairs Agency and the Ministry of the Environment, covering dietary health impact and residue standards, effects on living organisms in the human environment, water quality, honeybee impact and user safety. The twelve-month standard period describes one body’s target for its own step. The elapsed figure reflects the whole chain, and it is the one that governs your plan.

This is what makes Track 4 expensive. A filing that lands after the deadline waits for the re-evaluation to conclude, and conclusion is running at close to four years, not one. On a change registration already carrying a nine-month clock of its own, missing the data-submission deadline is not a quarter’s slippage. It is most of a product cycle.

It also reframes the earlier tracks. Filing two or more years ahead of the deadline, which keeps you on a normal review, is not merely the tidiest option. On these numbers it is the difference between a review measured in months and a wait measured in years.

There is also an engagement dimension. Re-evaluation is the moment when the data requirements and risk assessment applying to an active are actively reconsidered rather than settled. For a company whose portfolio depends on that active, that is the point at which argument is possible.

What this means for planning

Working back from a target launch:

• Treat 18 months as the floor for a new active, and note that a standard processing period is the reviewing body’s own target, generally excluding time while the file sits with the applicant for correction.
• Decide the applicant of record early. The registration will sit with them, and the foreign-manufacturer route is a theoretical option rather than a practical one.
• Scope translation from the four carve-outs, not from a blanket assumption in either direction.
• Budget the extension cycle, not just the entry. Nine months per additional crop or pest is what shapes a portfolio timeline.
• Plan for re-evaluation as a standing cost against registrations you already hold.

If you want that plan built for a specific product, the starting point is a registration assessment: active ingredient, formulation, target crops, and what you already hold, returned as a pathway, a gap list, and a timeline.

The gap between published and actual is itself an engagement question

There is a second reading of the numbers above, and it is the one most companies never act on.

A standard processing period is not an informal estimate. It is set and published under Article 6 of the Administrative Procedure Act. That article makes publication a legal obligation once a period has been set, though setting one is a best-efforts duty and there is no statutory requirement to actually meet it. So a company has no enforceable right to a decision within the published time.

What it does have is a benchmark the government set for itself, published under statute, and a public record showing the distance between that benchmark and the outcome. In pesticide re-evaluation that distance is a factor of nearly four, evidenced entirely by MAFF’s own tables. That is not a complaint. It is an argument with a citation.

Arguments of that kind have somewhere to go. Processing times are a standing subject for the Cabinet Office’s regulatory reform machinery, for industry associations making sector-wide submissions, for public comment on procedural revisions, and for direct dialogue with the division that owns the procedure. Where a delay has commercial consequences that are demonstrable rather than asserted, such as a product held out of a planting season or an investment deferred, that evidence is what the argument runs on.

Two honest limits, because the alternative is selling something that does not work.

This is a collective problem more than an individual one. A single company raising its own file rarely moves a processing time, and can strain the relationship it depends on. What moves the position is repeated, documented evidence across multiple companies, usually carried by an association, showing a pattern rather than a grievance. That changes who should make the argument and how it should be framed.

It is slow, and it is not a route to accelerating your own application. Nothing here shortens a review already under way. The realistic goal is structural: resourcing, sequencing between the bodies involved, or a revision to the published period so that planning assumptions match reality. Companies wanting their own file expedited should look at the filing-date decision above, which they control, rather than at advocacy, which they do not.

Handled properly, though, this is one of the clearer cases in Japanese public affairs where the evidence is public, the benchmark is the government’s own, and the argument is available to anyone prepared to assemble it.

Where this becomes a public affairs question

Most of the above is regulatory work. We do it for foreign agrochemical companies as a managed process: feasibility and gap assessment, coordinating the laboratories that generate the data, assembling the dossier in the accepted format with the Japanese summaries, the pre-submission contact and filing with FAMIC, every round of review questions, and then extensions, re-evaluation, and reporting. We do not run the studies, and we do not compete with the laboratories that do. Details are on our Japan pesticide registration support page. The public affairs questions sit around the edges: when a residue standard or an ADI determination shapes whether a product is commercially viable, when a re-evaluation outcome threatens a registration already on the market, when the applicable data requirements are themselves under revision, and when a use pattern matters enough that the argument needs to be made while the rules are being written rather than after.

The processing-period gap set out above belongs on that list too, with the caveats attached to it. It is not a route to accelerating your own file. It is a case to be made collectively, over time, about whether the published periods are a realistic account of what the system delivers, and it is one of the few arguments in Japanese regulatory advocacy where the evidence is public, the benchmark is the government’s own, and the record showing the distance is published by the ministry that set it. Making that case well means assembling the commercial consequence across several companies, working through the industry body that carries it, and putting it into the channels where procedural questions are actually decided: Cabinet Office regulatory reform, public comment on amendments, and the division that owns the procedure.

If that is the position you are in, request a registration assessment or get in touch.

Further guides: data requirements, generic and off-patent registration, re-evaluation, FAMIC, and the two routes for foreign manufacturers.

Further reading: the market-entry regulatory checklist maps which institutions apply to your sector, and the policy calendar sets out when rules are decided rather than applied.